Evidence map›Paper›PMID 42859273›Full record

ArticleAngiogenesis2026

Angiogenesis: a research field in full bloom.

Andrew C Dudley, Arjan W Griffioen

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Angiogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andrew C DudleyDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, & The UVA Comprehensive Cancer Center, Charlottesville, VA, 22908, USA. acd2g@virginia.edu.
Arjan W GriffioenAngiogenesis Laboratory, Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.griffioen@amsterdamumc.nl.

Funding

NIH HHS RO1CA177875 and RO1CA258451
6 · The paper itself

Abstract

It is with great pleasure that we announce the new journal impact factor for Angiogenesis: 11.2. This milestone reflects the vitality of our field and the extraordinary quality of the research our authors continue to entrust to us. Angiogenesis remains the premier international, peer-reviewed journal devoted to the cellular and molecular mechanisms that govern blood vessel formation in health and disease, and this new metric confirms what we have long believed: the science of vascular biology has never been more central to biomedicine.

Indexed as

AngiogenesisBiomedical ResearchNeovascularization, PhysiologicAnimalsHumansJournal Impact FactorPeriodicals as Topic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.